These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31856840)

  • 21. Comparison of proton-based definitive chemoradiotherapy and surgery-based therapy for esophageal squamous cell carcinoma: a multi-center retrospective Japanese cohort study.
    Ogawa K; Ishikawa H; Toyozumi T; Noma K; Kono K; Hojo H; Tamamura H; Azami Y; Ishida T; Nabeya Y; Iwata H; Araya M; Tokumaru S; Maruo K; Oda T; Matsubara H
    Esophagus; 2024 Oct; 21(4):484-494. PubMed ID: 38844703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Definitive Chemoradiotherapy Compared to Neoadjuvant Chemoradiotherapy With Esophagectomy for Locoregional Esophageal Cancer: National Population-based Cohort Study.
    Kamarajah SK; Phillips AW; Hanna GB; Low D; Markar SR
    Ann Surg; 2022 Mar; 275(3):526-533. PubMed ID: 32865948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of image-guided radiotherapy for rectal cancer patients treated with neoadjuvant concurrent chemoradiotherapy: A population-based propensity score-matched analysis.
    Li CC; Liang JA; Chen WT; Chien CR
    Asia Pac J Clin Oncol; 2019 Oct; 15(5):e197-e203. PubMed ID: 31250970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis.
    Worrell SG; Towe CW; A Dorth J; Machtay M; Perry Y; Linden PA
    Ann Surg Oncol; 2020 Feb; 27(2):500-508. PubMed ID: 31571054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Propensity-matched study on locally advanced esophageal cancer: surgery versus post-operative radiotherapy.
    Zeng Y; Su X; Zhou T; Jia J; Liu J; Yu W; Zhang Q; Song X; Fu X; Cai X
    Radiat Oncol; 2024 Sep; 19(1):130. PubMed ID: 39334405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer after Neoadjuvant Chemoradiotherapy: A Retrospective Study.
    Li J; Zhou X; Liu Y; Zhu J; Wan G; Wang Y; Leng X; Han Y; Peng L; Wu L; Wang Q
    Ann Surg Oncol; 2024 Jun; 31(6):3803-3812. PubMed ID: 38280959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical vs nonsurgical treatment for esophageal squamous cell carcinoma in patients older than 70 years: a propensity score matching analysis.
    Li K; Li C; Nie X; He W; Du K; Liu K; Wang C; Li J; Han Y; Peng L; Wang Q; Leng X
    J Gastrointest Surg; 2024 May; 28(5):611-620. PubMed ID: 38704198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of neoadjuvant concurrent chemoradiotherapy versus up-front proctectomy in clinical stage II-III rectal cancer: A population-based study.
    Ke TW; Liao YM; Chiang HC; Chang SC; Wang PH; Chen YY; Chen WT; Chien CR
    Asia Pac J Clin Oncol; 2016 Jun; 12(2):e234-40. PubMed ID: 24571424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of change in the Naples prognostic score after neoadjuvant chemoradiotherapy on survival in esophageal squamous cell carcinoma patients.
    Zhang H; Xiao X; Luan S; Li X; Sun S; Yuan Y
    Saudi Med J; 2024 May; 45(5):481-489. PubMed ID: 38734428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study.
    Lin CY; Lien MY; Chen CC; Fang HY; Lin YS; Chen CK; Chen JX; Lu TY; Huang TM; Hsieh TC; Sun SS; Li CC; Chien CR
    BMC Gastroenterol; 2022 Aug; 22(1):381. PubMed ID: 35948871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
    Hong ZN; Gao L; Weng K; Huang Z; Han W; Kang M
    Front Immunol; 2022; 13():836338. PubMed ID: 35300335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival outcome of esophagectomy and chemoradiotherapy for resectable esophageal squamous cell carcinoma in patients >75 years of age.
    Mayanagi S; Inoue M; Tokizawa K; Fushiki K; Tsushima T; Yokota T; Yamazaki K; Yasui H; Tsubosa Y
    Thorac Cancer; 2024 Jul; 15(21):1656-1664. PubMed ID: 38898742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
    Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Lordick F; D'Journo XB; Cerfolio RJ; Korst RJ; Novoa NM; Swanson SJ; Brunelli A; Ismail M; Fernando HC; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J;
    J Clin Oncol; 2018 Sep; 36(27):2796-2803. PubMed ID: 30089078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nomogram based on pretreatment hepatic and renal function indicators for survival prediction of locally advanced esophageal squamous cell carcinoma with treatment of neoadjuvant chemoradiotherapy plus surgery.
    Lin XW; Chen H; Xie XY; Liu CT; Lin YW; Xu YW; Wang XJ; Wu FC
    Updates Surg; 2024 Aug; 76(4):1377-1388. PubMed ID: 37957531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer.
    Macedo FI; Mesquita-Neto JW; Kelly KN; Azab B; Yakoub D; Merchant NB; Livingstone AS; Franceschi D
    Ann Surg Oncol; 2020 Mar; 27(3):662-670. PubMed ID: 31788752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical impact of the interval between chemoradiotherapy and esophagectomy in esophageal squamous cell carcinoma patients.
    Wang BY; Chen HS; Hsu PK; Shih CS; Liu CY; Liu CC; Wu SC
    Ann Thorac Surg; 2015 Mar; 99(3):947-55. PubMed ID: 25620588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.